Action MIRA MIRA PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués MIRA Pharmaceuticals, Inc.

Actions

MIRA

US60458C1045

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 20/06/2024 		Varia. 5j. Varia. 1 janv.
0,732 USD +3,10% Graphique intraday de MIRA Pharmaceuticals, Inc. +3,08% -30,29%
10/06 MIRA Pharmaceuticals, Inc. annonce des résultats précliniques positifs pour son nouvel analogue oral de la kétamine, Ketamir-2, ouvrant la voie à la soumission d'une demande d'IND plus tard cette année CI
29/05 Mise a jour sectorielle : Les actions du secteur de la sante chutent en fin d'apres-midi MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
PR
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
PR
MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog
PR
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog
PR
Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
PR
MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor
PR
MIRA Pharmaceuticals Provides Corporate Update
PR
MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations
PR
MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%
PR
MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time
PR
MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a
PR
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
PR
MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot
PR
MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts
PR
MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit
PR
MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action MIRA
  4. Actualités MIRA Pharmaceuticals, Inc.
  5. Communiqués